Key facts
- This page summarizes Therapeutics ApS Alteral's Form 4 filing for Nordicus Partners Corp (NORD).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 10 Dec 2024, 14:04.
Therapeutics ApS Alteral - 12 Nov 2024 Form 4 Insider Report for Nordicus Partners Corp (NORD)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- NORD
- Reported as of
- 12 Nov 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Dec 2024, 14:04:35 UTC
- Prior SEC filing
- 05 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Allan Traugott Wehnert
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Therapeutics ApS Alteral filed Form 4 for Nordicus Partners Corp (NORD) on 10 Dec 2024.
Change
- Previous filing in this sequence was filed on 05 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NORD
transaction
Common stock
Other
- Transaction value
- Shares
- +4,030,903
- Change %
- +319%
- Price
- Shares after
- 5,296,131
- Date
- 12 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares acquired in connection with the acquisition by Nordicus Partners Corporation through a share exchange with the shareholders of Bio-Convert ApS on November 12, 2024.